Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Upfront Ruxolitinib for Chronic Graft-vs-host Disease
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT06695507
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Ruxolitinib Vs Prednisone As First-line Therapy for CGVHD Needing Systemic Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Target Recruit Count
- 120
- Registration Number
- NCT06660355
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06619522
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06616155
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Ruxolitinib Treatment in Inclusion Body Myositis
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 80
- Registration Number
- NCT06536166
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06479135
- Locations
- 🇺🇸
Mission Cancer + Blood, Des Moines, Iowa, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 220
- Registration Number
- NCT06477549
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06462469
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT06457425
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.